Rheumatoid arthritis and gastric sleeve surgery present a complex clinical intersection that requires careful multidisciplinary planning. People living with rheumatoid arthritis (RA) face a disproportionately high risk of obesity due to reduced mobility, corticosteroid use, and chronic systemic inflammation — making bariatric surgery an increasingly relevant consideration. Sleeve gastrectomy may offer meaningful benefits for eligible patients, including reduced joint load and improved metabolic health. However, RA introduces unique challenges around surgical risk, immunosuppressive medication management, and post-operative recovery that demand close collaboration between rheumatology, bariatric, anaesthetic, and pharmacy teams.

How Rheumatoid Arthritis Affects Eligibility for Gastric Sleeve Surgery

RA patients may be eligible for gastric sleeve surgery under NICE CG189 if they meet BMI thresholds, though RA itself is not a listed qualifying comorbidity; stable, well-controlled disease and multidisciplinary assessment are essential before proceeding.

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune condition characterised by joint inflammation, fatigue, and progressive disability. Obesity is disproportionately common among people with RA, partly due to reduced mobility, corticosteroid use, and the inflammatory milieu that promotes adipose tissue accumulation. For many patients, bariatric surgery — including sleeve gastrectomy — represents a meaningful opportunity to reduce weight-related disease burden.

Not sure if this is normal? Chat with one of our pharmacists →

In the UK, eligibility criteria for bariatric surgery are set out in NICE CG189 (Obesity: identification, assessment and management) and are subject to local NHS integrated care board (ICB) commissioning policies. NICE CG189 recommends that bariatric surgery be considered for adults with a BMI of 40 kg/m² or above, or between 35–39.9 kg/m² with a significant obesity-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea (OSA), or dyslipidaemia. In people with type 2 diabetes, lower BMI thresholds may apply in certain circumstances, in line with updated NICE guidance. RA itself is not a listed qualifying comorbidity, but its associated conditions — including type 2 diabetes, cardiovascular disease, and metabolic syndrome — may support eligibility in clinical discussions.

NHS pathways typically require patients to complete a tier 3 specialist weight management programme (providing structured dietary, psychological, and physical activity support) before referral to a tier 4 bariatric surgical service, though this may vary by ICB.

Eligibility assessment for gastric sleeve surgery in patients with RA requires careful multidisciplinary evaluation. Key considerations include:

• Disease activity: Active, poorly controlled RA may increase surgical and anaesthetic risk

• Immunosuppressive therapy: Certain medications require pre-operative adjustment

• Functional status: Severe joint damage may affect post-operative rehabilitation

• Nutritional status: Baseline deficiencies are common in RA and must be addressed pre-operatively

Patients should be assessed by both a bariatric surgical team and their rheumatologist before proceeding. Stable, well-controlled RA is generally considered more compatible with safe surgical outcomes, though each case must be evaluated individually.

Risks and Considerations for RA Patients Undergoing Bariatric Surgery

RA increases peri-operative risks including impaired wound healing, infection susceptibility, cervical spine instability during intubation, anaemia, osteoporosis, and elevated VTE risk, all requiring pre-operative assessment and mitigation.

Gastric sleeve surgery carries inherent surgical risks that may be amplified in patients with RA. The chronic inflammatory state associated with RA can impair wound healing, increase susceptibility to infection, and elevate cardiovascular risk — all of which are relevant in the peri-operative period. Patients on long-term corticosteroids may require peri-operative steroid stress dosing to prevent adrenal insufficiency; this should be managed in accordance with Association of Anaesthetists and Royal College of Anaesthetists (RCoA) guidance, in liaison with the anaesthetic team.

Immunosuppressive and biologic therapies used in RA management — such as methotrexate, leflunomide, and tumour necrosis factor (TNF) inhibitors — can affect immune function and potentially influence the risk of post-operative infection or delayed healing. Peri-operative management of these agents should follow British Society for Rheumatology (BSR) and UKCPA guidance (see below and the medication section).

Additional considerations specific to RA patients include:

• Cervical spine instability: Atlantoaxial subluxation can occur in longstanding RA and poses a risk during intubation and anaesthesia. Pre-operative cervical spine assessment and airway planning should be considered in patients with significant or longstanding disease, in line with anaesthetic team recommendations

• Anaemia: Chronic disease-related anaemia is common and should be optimised before surgery

• Osteoporosis: Prevalent in RA, particularly with corticosteroid use, increasing fracture risk post-operatively

• Venous thromboembolism (VTE): Both RA and obesity independently elevate VTE risk; robust prophylaxis in line with local bariatric protocols is essential

A thorough pre-operative assessment involving rheumatology, anaesthetics, and the bariatric team is essential to mitigate these risks and ensure the patient is in the best possible condition before surgery.

Managing RA Medications Before and After Gastric Sleeve Surgery

Immunosuppressive and biologic medications require careful peri-operative adjustment guided by BSR and UKCPA guidance; NSAIDs should be avoided post-operatively, and methotrexate must never be crushed outside controlled clinical procedures.

Medication management is one of the most clinically complex aspects of preparing an RA patient for gastric sleeve surgery. Decisions should be made in close collaboration between the rheumatology team, bariatric team, and a specialist pharmacist, with reference to BSR peri-operative guidance and the UKCPA Handbook of Perioperative Medicines.

Conventional DMARDs

Methotrexate is generally continued peri-operatively in most patients, in line with BSR guidance, as stopping it increases the risk of RA flare. However, individual risk assessment is required, taking into account renal function, infection risk, and wound-healing concerns. If oral absorption or tolerance is a concern in the early post-operative period, switching to a subcutaneous formulation may be considered in discussion with the rheumatology team. Leflunomide has a long half-life and its timing requires careful individual assessment; in some circumstances a washout procedure may be considered.

Biologic agents

TNF inhibitors (such as adalimumab and etanercept) and other biologic agents are typically withheld for one dosing interval prior to elective surgery, as recommended by the BSR, and restarted once surgical wounds have healed satisfactorily — usually within two to four weeks post-operatively, provided there is no evidence of infection.

JAK inhibitors

JAK inhibitors (such as baricitinib, tofacitinib, and upadacitinib) are generally held for approximately three to seven days before surgery, in line with UKCPA and BSR guidance. The exact timing should be confirmed with the rheumatology team and specialist pharmacist on an individual basis.

Rituximab

For patients receiving rituximab, elective surgery should ideally be planned towards the end of the dosing cycle, when B-cell counts are beginning to recover. Timing should be agreed with the rheumatology team.

NSAIDs

Non-steroidal anti-inflammatory drugs (NSAIDs) should generally be avoided following sleeve gastrectomy due to the increased risk of gastric ulceration and staple-line complications. This is an important consideration for RA patients who may rely on NSAIDs for symptom control. If NSAID use is considered absolutely necessary, this should only be on the advice of the bariatric or surgical team, with concurrent gastroprotection (proton pump inhibitor, PPI). Alternative analgesic and anti-inflammatory strategies should be discussed with the rheumatology team before surgery.

Drug formulation and absorption

Sleeve gastrectomy is primarily a restrictive procedure and does not cause significant malabsorption. However, the reduced gastric volume and altered gastric physiology in the early post-operative period may affect tolerability and absorption of some oral medications. Patients should:

• Seek pharmacy advice before altering the form of any medication

• Avoid modified-release formulations unless specifically approved by a pharmacist or prescriber

• Never crush or split cytotoxic or teratogenic medicines such as methotrexate outside of controlled clinical procedures; specialist pharmacy guidance must be sought

• Take medications in soluble or liquid form where available and approved, particularly in the early post-operative period

• Report any new or worsening joint symptoms promptly, as RA flares may occur during the peri-operative period

Patients and carers should also be aware that suspected side effects from any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Close liaison between the rheumatology, bariatric, and pharmacy teams is essential throughout this process.

How Weight Loss Surgery May Influence Rheumatoid Arthritis Symptoms

Significant weight loss following bariatric surgery may reduce systemic inflammation and mechanical joint load, potentially improving RA symptoms, though the evidence is largely observational and surgery is not a substitute for established RA therapies.

There is growing evidence to suggest that significant weight loss following bariatric surgery may have a beneficial effect on inflammatory arthritis, including RA. Adipose tissue is metabolically active and produces pro-inflammatory cytokines — including interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) — which contribute to systemic inflammation and may exacerbate RA disease activity. Reducing adipose tissue through sustained weight loss may therefore help to lower the overall inflammatory burden, though a direct causal relationship has not been firmly established.

Several observational studies and cohort analyses have reported improvements in disease activity scores, patient-reported outcomes, and physical function following bariatric surgery in patients with inflammatory arthritis. Reduced mechanical load on weight-bearing joints — particularly the knees, hips, and ankles — is an additional benefit, potentially improving mobility and reducing pain independent of immunological effects.

However, it is important to note that bariatric surgery is not an approved or recommended treatment for RA, and the evidence base remains largely observational rather than from randomised controlled trials. Patients should be counselled that:

• Weight loss surgery is not a substitute for established RA therapies; DMARD and biologic treatment should continue as clinically indicated

• Disease activity should continue to be monitored closely post-operatively

• Some patients may experience a temporary RA flare in the peri-operative period due to surgical stress or medication interruption

• Long-term outcomes in terms of RA remission rates require further research

Nonetheless, the potential for improved metabolic health, reduced cardiovascular risk, and enhanced quality of life makes bariatric surgery a worthwhile consideration for eligible patients with RA and significant obesity.

Post-Operative Care and Monitoring for Patients with RA

RA patients require structured post-operative monitoring covering nutritional deficiencies, gastroprotection, RA disease activity via DAS28, and prompt recognition of red-flag symptoms such as tachycardia, severe abdominal pain, or breathlessness.

Following gastric sleeve surgery, patients with RA require a structured and closely monitored recovery plan that addresses both the post-bariatric and rheumatological aspects of their care.

Urgent red flags — seek emergency care immediately (call 999 or go to A&E)

Patients and carers should be aware of the following warning signs, which may indicate serious post-operative complications such as staple-line leak or pulmonary embolism:

• Rapid or irregular heartbeat (tachycardia)

• Severe abdominal, chest, or left shoulder pain

• Breathlessness or difficulty breathing

• Persistent vomiting or inability to tolerate fluids

• High temperature with signs of systemic illness

These symptoms may present atypically in patients on immunosuppressive therapy, as the usual inflammatory markers of infection (such as fever or raised inflammatory markers) may be blunted. A low threshold for investigation is therefore warranted.

Nutritional monitoring

Sleeve gastrectomy is primarily a restrictive procedure; it reduces gastric capacity but does not cause significant malabsorption. However, the reduced dietary intake and altered gastric physiology — combined with pre-existing nutritional deficiencies common in RA — increase the risk of deficiencies in:

• Iron (especially relevant in women and those with chronic anaemia)

• Vitamin B12 and folate (critical given methotrexate's antifolate mechanism)

• Vitamin D and calcium (important given the elevated osteoporosis risk in RA)

• Zinc and other micronutrients

Lifelong nutritional supplementation and regular blood monitoring are standard practice following bariatric surgery, in line with BOMSS (British Obesity and Metabolic Surgery Society) postoperative monitoring and supplementation schedules. These should be coordinated with the rheumatology team to avoid interactions or masking of deficiency symptoms.

Gastroprotection

Many UK bariatric centres routinely prescribe a proton pump inhibitor (PPI) following sleeve gastrectomy to protect the staple line and reduce the risk of gastric ulceration. Patients should follow their surgical team's local protocol regarding PPI use and duration.

RA disease monitoring

RA disease activity should be formally reassessed at regular intervals post-operatively using validated tools such as the DAS28 score. Patients should be advised to contact their GP or rheumatology team promptly if they experience:

• A significant flare of joint pain or swelling

• Signs of infection, including fever or wound changes

• Difficulty swallowing or tolerating medications

• Symptoms suggestive of nutritional deficiency, such as fatigue, paraesthesia, or hair loss

A shared care plan between the bariatric and rheumatology teams, with clear communication pathways, is essential for safe long-term management.

NHS Referral Pathways and Specialist Guidance for RA and Obesity

Patients with RA and obesity should be referred to a tier 3 weight management service in the first instance, with early rheumatologist involvement to confirm disease stability, guide medication management, and contribute to the bariatric MDT discussion.

In England, access to bariatric surgery on the NHS is governed by NICE CG189 (Obesity: identification, assessment and management) and local NHS ICB commissioning policies, which may vary across regions. Patients with RA who meet the BMI thresholds outlined in NICE CG189 should be referred to a tier 3 specialist weight management service in the first instance. These services provide structured, multidisciplinary interventions — including dietary support, psychological assessment, and physical activity guidance — before surgical referral to a tier 4 bariatric service is considered. In people with type 2 diabetes, lower BMI thresholds may apply in certain circumstances; patients should discuss this with their GP or specialist.

For patients with RA, the referral process should ideally involve early communication between the GP, rheumatologist, and the weight management team. The rheumatologist plays a key role in:

• Confirming disease stability and optimising RA control prior to surgical assessment

• Advising on medication management in the peri-operative period, in line with BSR and UKCPA guidance

• Providing input into the multidisciplinary team (MDT) discussion regarding surgical suitability

• Coordinating post-operative monitoring and DMARD reintroduction

The British Society for Rheumatology (BSR) and British Obesity and Metabolic Surgery Society (BOMSS) both provide professional guidance relevant to this patient group, and clinicians are encouraged to refer to these resources when managing complex cases. For medicine-specific peri-operative decisions, the MHRA Summary of Product Characteristics (SmPC), available via the electronic Medicines Compendium (emc), is the primary UK regulatory reference; EMA European Public Assessment Reports (EPARs) may be used as a secondary source where relevant.

Patients are encouraged to discuss their interest in bariatric surgery openly with their GP and rheumatologist. Shared decision-making — taking into account disease activity, medication regimen, nutritional status, and personal goals — is central to identifying those most likely to benefit safely from surgery. With appropriate planning and specialist collaboration, gastric sleeve surgery can be a safe and potentially beneficial intervention for carefully selected patients living with both RA and obesity.

Suspected side effects from any medicine should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions